Myokardia Inc Quick Ratio (MYOK) starting from the third quarter 2020 to third quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Myokardia Inc   (NASDAQ: MYOK)

Myokardia Inc 's Quick Ratio

MYOK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2020, Quick Ratio fell to 17.07 above Myokardia Inc average.

Within Major Pharmaceutical Preparations industry 68 other companies have achieved higher Quick Ratio than Myokardia Inc in third quarter 2020. While Quick Ratio total ranking in the third quarter 2020 has deteriorated compared to the prior quarter from 137 to 235.

Explain Quick Ratio?
How much Cash & cash equivalents MYOK´s has?
What are MYOK´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MYOK Quick Ratio (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3
Y / Y Current Liabilities Change 19.06 % 38.04 % 45.92 % 102.13 % -1.13 %
Y / Y Cash & cash equivalent Change 114.79 % 64.38 % -37.36 % 32.24 % 10.01 %
Quick Ratio MRQ 17.07 20.87 7.67 8.69 9.46
MYOK's Total Ranking # 235 # 137 # 528 # 468 # 421
Seq. Current Liabilities Change 19.32 % -3.66 % -4.7 % 8.68 % 38.34 %
Seq. Cash & cash equivalent Change -2.42 % 162.29 % -15.89 % -0.23 % -25.32 %



Quick Ratio third quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 102
Overall Market # 235


Quick Ratio Statistics
High Average Low
20.87 9.09 3.24
(Jun 30 2020)   (Sep 30 2015)




Financial Statements
Myokardia Inc 's Current Liabilities $ 52 Millions Visit MYOK's Balance sheet
Myokardia Inc 's Cash & cash equivalent $ 896 Millions Visit MYOK's Balance sheet
Source of MYOK's Sales Visit MYOK's Sales by Geography


Cumulative Myokardia Inc 's Quick Ratio

MYOK's Quick Ratio for the trailling 12 Months

MYOK Quick Ratio

 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth 45.13 % 38.19 % 15.63 % -0.83 % -28.34 %
Y / Y Cash & cash equivalent TTM Growth 39.53 % 16.02 % 5.48 % 48.2 % 46.99 %
Quick Ratio TTM 13.58 11.57 10.27 12.57 14.12
Total Ranking TTM # 3956 # 138 # 3914 # 3799 # 3788
Seq. Current Liabilities TTM Growth 4.63 % 7.15 % 9.26 % 18.49 % -0.38 %
Seq. Cash & cash equivalent TTM Growth 22.79 % 20.64 % -10.7 % 5.49 % 2.1 %

Quick ratio ranking by company, industry and sector >> Back to MYOK Financial Strength Comparisons >> Go to Compare MYOK Quick Ratio to its Competitors

On the trailing twelve months basis MYOK Cash & cash equivalent more than doubled by 114.79 % in Q3 2020 year on year, faster than Current Liabilities, this led to increase in in Myokardia Inc 's Quick Ratio to 13.58, above MYOK average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 454 other companies have achieved higher Quick Ratio than Myokardia Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2020 from 138 to 3956.

Explain Quick Ratio?
How much Cash & cash equivalents MYOK´s has?
What are MYOK´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 455
Healthcare Sector # 859
Within the Market # 3956


trailing twelve months Quick Ratio Statistics
High Average Low
13.58 7.92 2.58
(Sep 30 2020)   (Mar 31 2016)




Companies with similar Quick Ratio in the quarter ending Sep 30 2020, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2020 MRQ Cash & cash equivalentSep 30 2020 MRQ Current Liabilities
Lantern Pharma Inc   45.07 $ 41.605  Millions$ 0.923  Millions
Psyence Biomedical ltd   44.85 $ 1.135  Millions$ 0.025  Millions
Arena Pharmaceuticals Inc   43.75 $ 1,167.864  Millions$ 26.697  Millions
Annexon Inc   41.24 $ 370.686  Millions$ 8.988  Millions
Xbiotech Inc   38.47 $ 238.431  Millions$ 6.198  Millions
Infinity Pharmaceuticals Inc   36.47 $ 41.285  Millions$ 1.132  Millions
Relmada Therapeutics Inc  36.33 $ 123.138  Millions$ 3.390  Millions
Alx Oncology Holdings Inc  36.05 $ 259.484  Millions$ 7.197  Millions
Nkarta Inc   34.50 $ 329.759  Millions$ 9.559  Millions
Repare Therapeutics Inc   34.13 $ 347.872  Millions$ 10.193  Millions
Trevena inc   33.47 $ 112.682  Millions$ 3.367  Millions
Arca Biopharma Inc  33.46 $ 51.095  Millions$ 1.527  Millions
Scorpius Holdings inc   30.85 $ 117.309  Millions$ 3.802  Millions
Generation Bio Co   30.60 $ 280.366  Millions$ 9.163  Millions
Monopar Therapeutics Inc   29.48 $ 17.983  Millions$ 0.610  Millions
Compass Pathways Plc  28.50 $ 196.534  Millions$ 6.895  Millions
Atreca inc   27.95 $ 259.264  Millions$ 9.275  Millions
Viking Therapeutics Inc   27.18 $ 255.304  Millions$ 9.392  Millions
Oric Pharmaceuticals Inc   26.94 $ 186.610  Millions$ 6.928  Millions
Pliant Therapeutics Inc   26.66 $ 294.000  Millions$ 11.026  Millions
Metacrine Inc   26.63 $ 109.239  Millions$ 4.102  Millions
Tff Pharmaceuticals Inc  26.45 $ 41.618  Millions$ 1.573  Millions
Assembly Biosciences Inc   26.39 $ 237.941  Millions$ 9.015  Millions
Matinas Biopharma Holdings Inc   26.28 $ 62.771  Millions$ 2.388  Millions
Zomedica Corp   25.13 $ 52.033  Millions$ 2.070  Millions
Atrium Therapeutics Inc   24.94 $ 341.142  Millions$ 13.680  Millions
Akero Therapeutics Inc   24.29 $ 291.870  Millions$ 12.014  Millions
Kezar Life Sciences Inc   24.21 $ 149.954  Millions$ 6.193  Millions
89bio Inc   23.25 $ 219.153  Millions$ 9.424  Millions
Exicure Inc   22.78 $ 94.080  Millions$ 4.130  Millions

Date modified: 2026-08-29T17:33:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.